3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF
First Claim
Patent Images
1. A daily dosage thyroid hormone composition comprising T3S as the active principle, in a quantity ranging from 1 to 1000 μ
- g;
at least one diluent selected from the group consisting of;
microcrystalline cellulose, calcium carbonate, magnesium carbonate, and mixtures thereof;
at least one glidant selected from the group consisting of;
glycerol dibenhate and talc;
at least one lubricant selected from the group consisting of;
magnesium stearate, zinc stearate, and colloidal silica; and
at least one disintegrant selected from the group consisting of;
croscarmellose or salts thereof and crosovidone or salts thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
-
Citations
29 Claims
-
1. A daily dosage thyroid hormone composition comprising T3S as the active principle, in a quantity ranging from 1 to 1000 μ
- g;
at least one diluent selected from the group consisting of;
microcrystalline cellulose, calcium carbonate, magnesium carbonate, and mixtures thereof;at least one glidant selected from the group consisting of;
glycerol dibenhate and talc;at least one lubricant selected from the group consisting of;
magnesium stearate, zinc stearate, and colloidal silica; andat least one disintegrant selected from the group consisting of;
croscarmellose or salts thereof and crosovidone or salts thereof. - View Dependent Claims (2, 3, 4, 9, 12, 13, 15, 23, 24, 25, 26, 28, 29)
- g;
-
5-8. -8. (canceled)
-
10. (canceled)
-
11. (canceled)
-
14. (canceled)
-
16-21. -21. (canceled)
-
22. (canceled)
-
27. (canceled)
Specification